Week of December 17, 2012: Malvern Instruments Opens New Applications Laboratory in Brazil; Roche To Invest in Diagnostics Production in Germany; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of December 17, 2012: Malvern Instruments Opens New Applications Laboratory in Brazil; Roche To Invest in Diagnostics Production in Germany; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Malvern Instruments has opened a new applications laboratory in São Paulo, Brazil, to support business growth in South America. The facility will be equipped with instruments spanning Malvern’s range of particle characterization, protein measurement, and rheology systems.

Roche plans to invest more than CHF 240 million (USD 263 million) in diagnostics production at its Penzberg biotechnology center near Munich, Germany. The plans call for construction of a new production facility, to be known as Diagnostics Operations Complex II. The facility is scheduled to be operational in December 2014 and will create 50 new jobs. Read More

Teva Pharmaceutical Industries and Handok Pharmaceuticals have agreed to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market. Under the agreement, Teva will be responsible for manufacturing and supplying medicines. Handok’s primary responsibility will be in sales and marketing, distribution, and regulatory affairs. Teva will have a controlling stake in the new business venture, with a profit split of 51/49% to Teva and Handok, respectively. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here